This article was originally published in The Gray Sheet
Will receive $10.5 mil. if all outstanding Class A and Class B warrants expiring Aug. 18 are exercised. The Class A warrants have a $1.50 exercise price for one share of ANMR common stock and one Class B warrant. The Class B warrants have a $2 exercise price for one share of ANMR common stock. Proceeds "would be used for the development of two new clinical MRI devices and further expansion of [the company's] manufacturing facilities to meet its contractual commitments," according to the Wilmington, Massachusetts firm.
You may also be interested in...
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.